and adjustments to ratings and price targets. Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Quest Diagnostics's ...

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

Investment analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of Quest ...

Barclays analyst Luke Sergott maintained a Hold rating on Quest Diagnostics (DGX – Research Report) today and set a price target of $175.00.

Detailed price information for Henry Schein Inc (HSIC-Q) from The Globe and Mail including charting and trades.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN – Research Report) and Align Tech (ALGN – Research Report). Stay Ahead of the Mar ...

Valued at a market cap of $18.2 billion, Quest Diagnostics Incorporated (DGX) provides diagnostic testing and services in the ...

GRAIL's groundbreaking Galleri test, detecting 50+ cancers, FDA status, and strategic growth make it a top investment with ...

In the wake of the stock market’s selloff, 125 of the 855 US-listed stocks Morningstar covers now sit at 5 stars, signaling ...

Buying $1000 In DGX: If an investor had bought $1000 of DGX stock 5 years ago, it would be worth $963,529.41 today based on a ...